SEYMOUR TAMARA A
Known title: DirectorCIK: 0001288232
SEYMOUR TAMARA A's purchase track record
How the stock did after each of SEYMOUR TAMARA A's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since May 20, 2022
Stock higher 6 months later
67%
3 months: 100%
Median 6-month return
+6.9%
3 months: +11.8%
Beat the S&P 500
33%
median -6.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2025 | ZVRA | $25K | +7.5% | +28.8% | +0.7% |
| 3/17/2023 | ZVRA | $3K | +21.0% | +6.9% | +13.6% |
| 5/20/2022 | ZVRA | $974 | +11.8% | -6.8% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZVRA | ▲ Buy | Open Market | 3,175 | $25K | 9/12/2025 | View on chart |
| ZVRA | ▲ Buy | Open Market | 519 | $3K | 3/17/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 200 | $974 | 5/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.